Table 2. Characteristics of candidate biomarkers in both discovery and validation cohorts.
| m/z | Tendency1 | Discovery cohort | Validation cohort | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ave (C)2 | Ave (N)3 | P-value4 | AUC5 | 95% CI6 | Ave(C)2 | Ave (N)3 | P-value4 | AUC5 | 95% CI6 | ||
| 1895.3 | ↑ | 2664.8 | 374.7 | <0.001 | 0.838 | (0.780-0.895) | 2949.0 | 499.7 | <0.001 | 0.845 | (0.783-0.906) |
| 1944.0 | ↓ | 858.5 | 3103.8 | <0.001 | 0.906 | (0.863-0.949) | 918.3 | 2741.0 | <0.001 | 0.841 | (0.782-0.901) |
| 2020.9 | ↑ | 3328.8 | 320.5 | <0.001 | 0.746 | (0.671-0.822) | 4562.3 | 911.0 | <0.001 | 0.823 | (0.754-0.892) |
| 2080.7 | ↓ | 295.8 | 1187.9 | <0.001 | 0.896 | (0.849-0.942) | 221.2 | 1016.4 | <0.001 | 0.893 | (0.844-0.943) |
| 2104.5 | ↓ | 132.8 | 544.7 | <0.001 | 0.906 | (0.864-0.948) | 90.0 | 511.1 | <0.001 | 0.934 | (0.896-0.971) |
| 2656.8 | ↓ | 565.6 | 704.3 | <0.001 | 0.673 | (0.597-0.750) | 471.7 | 696.4 | <0.001 | 0.699 | (0.621-0.777) |
| 3154.9 | ↓ | 145.8 | 1566.3 | <0.001 | 0.980 | (0.963-0.996) | 132.6 | 1330.0 | <0.001 | 0.918 | (0.872-0.963) |
| 3238.5 | ↑ | 1015.9 | 451.2 | <0.001 | 0.623 | (0.545-0.701) | 680.4 | 456.9 | 0.456 | 0.535 | (0.450-0.619) |
| 3875.9 | ↓ | 349.7 | 557.3 | <0.001 | 0.733 | (0.660-0.806) | 248.3 | 509.1 | <0.001 | 0.759 | (0.685-0.834) |
| 4042.8 | ↓ | 271.5 | 940.5 | <0.001 | 0.859 | (0.802-0.916) | 112.1 | 824.1 | <0.001 | 0.897 | (0.849-0.945) |
1 Tendency↑represent the peaks intensity of CRC patients was higher than the controls,↓represent the peaks intensity of the CRC patients was lower than the controls; 2 Average intensity of peaks for the CRC patients; 3 Average intensity of peaks for the controls; 4 P-value calculated with the Wilcoxon test; 5 Area under ROC curve; 6 95% confidence intervals; P-value lower than 0.05 was considered statistically significant.